trending Market Intelligence /marketintelligence/en/news-insights/trending/b-YHcZBpIav9FKTbBnYHZA2 content esgSubNav
In This List

Lupin gets warning from US FDA after inspection of Mandideep facility

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Lupin gets warning from US FDA after inspection of Mandideep facility

Lupin Ltd. said the U.S. Food and Drug Administration recommended taking action against the company after inspecting its Mandideep facility in Madhya Pradesh, India.

Following the December inspection, the regulator warned the Indian drugmaker that it may withhold approval of its pending applications or supplements related to the facility.

The Mumbai-based company said no applications related to the facility are pending with the FDA and the warning will not have any impact on revenues and operations from the facility.

The maker of generic drugs added that it will send updates of its corrective actions to the agency and expects a positive outcome.